None listed
Conditions
Interventions
Group 1 Type of group
MK-0826 once a day, plus 2 placebo doses of the antibiotic Cefepime every 12 hours.
Group name:Group 2 Type of group
Cefepime every 12 hours, plus a placebo dose of the drug MK-0826.
Sponsors
MERCK SHARP & DOHME PERU S.R.L.,
Eligibility
Inclusion criteria
Inclusion criteria: N.A
Exclusion criteria
Exclusion criteria: • Patients under 18 years of age. • Patients who have received an effective antibiotic treatment for pneumonia for more than one day (24 hours). • Patients who have previously had serious allergies or other serious reactions to certain antibiotics, including Carbapenem, Cefepime or other penicillins or Cephalosporins or Metronidazole. • Patients who have a rapidly evolving disease or terminal illness. • Patients whose kidney or liver is working very poorly, determined by a blood test or those who require dialysis. • Patients who have AIDS or those who are taking medications that serve to lower the defenses (immunosuppressants). • Patients who are participating or have participated in another medical study that involves the use of a research drug, within the last 30 days or if you have participated in this study before. • Patients with lung cancer or cancer that has spread to the lung or cystic fibrosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:NA Measure:NA Timepoints:NA | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:NA Measure:NA Timepoints:NA | — |
Contacts
Public ContactStela Lopez
MERCK SHARP & DOHME PERU S.R.L
Outcome results
None listed